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Summary
Background.— Despite improvement in revascularization strategies, microvascular obstruction
(MO) lesions remain associated with poor outcome after ST-segment elevationmyocardial infarc-
tion (STEMI).
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Aims.— To establish a bedside-available score for predicting MO lesions in STEMI, with cardiac
magnetic resonance imaging (CMR) as the reference standard, and to test its prognostic value
for clinical outcome.
Methods.— Patients with STEMI of < 12 hours’ evolution treated by percutaneous coronary
intervention (PCI) were included. CMR was performed 4—8 days later, to measure myocardial
infarction (MI) extent, left ventricular ejection fraction (LVEF) and volumes, and to identify
MO lesions. An MO score was built from multivariable logistic regression results and included
clinical, angiographic and electrocardiographic criteria. Adverse cardiovascular events were
recorded prospectively after STEMI.
Results.— We analysed data from 112 patients. MO lesions were found in 63 (56%) patients and
were associated with larger MI as assessed by higher peak creatine phosphokinase (3755± 351
vs 1467± 220 IU, p < 0.001), lower LVEF (46.7± 1.5 vs 53.4± 1.6%, p < 0.01) and larger MI extent
(18.7± 1.2 vs 9.0± 1.3% LV, p < 0.001) on CMR. MO score > 4 accurately identiﬁed microcircula-
tory injuries (sensitivity 84%; speciﬁcity 82%) and independently predicted the presence of MO
lesions on CMR. MO score > 4 predicted adverse cardiovascular events during the ﬁrst year after
STEMI (relative risk 2.60 [1.10—6.60], p = 0.03).
Conclusions.— MO lesions are frequent in PCI-treated STEMI and are associated with larger MIs.
MO score accurately predicted MO lesions and identiﬁed patients with poor outcome post-STEMI.
© 2010 Elsevier Masson SAS. All rights reserved.
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Résumé
Contexte.— En dépit de l’amélioration des techniques de revascularisation, les lésions
microvasculaires obstructives (LMO) grèvent le pronostic évolutif des syndromes coronariens
aigus avec sus-decalage de ST (SCAST+).
Objectif.— Établir un score prédictif de présence de LMO après revascularisation des SCAST+
en utilisant l’IRM cardiaque comme méthode de référence.
Méthodes.— Les patients avec SCAST+ < 12 heures d’évolution et revascularisés par angioplastie
coronaire étaient éligibles. Une IRM cardiaque était réalisée quatre à huit jours après revas-
cularisation pour identiﬁer les LMO, mesurer l’extension de l’infarctus et calculer les volumes
et la fraction d’éjection du VG. Un score (MO score) a été construit sur la base des résultats
d’une analyse multivariée incluant des facteurs cliniques, électriques et angiographiques. Les
événements cardiaques défavorables ont été collectés dans le suivi.
Résultats.— Cent douze patients ont été inclus dans l’étude. Les LMO ont été identiﬁées
dans 56 % des cas et étaient associées à un infarctus plus étendu en IRM (18,7± 1,2 versus
9,0± 1,3 % VG, p < 0,001) et une FEVG plus basse (46,7± 1,5 versus 53,4± 1,6 %, p < 0,01). Une
valeur de MO score supérieure à 4 prédisait efﬁcacement la présence de LMO à l’IRM car-
diaque (sensibilité 84 %; spéciﬁcité 82 %). De plus, un MO score supérieur à 4 était un prédicteur
indépendant d’événements cliniques défavorables durant la première année après le SCAST+
(RR 2,6 [1,1—6,6], p = 0,03).
Conclusions.— Les LMO sont fréquentes après angioplastie coronaire dans les SCAST+ et asso-
ciées à un infarctus plus étendu. Un score simple base sur les paramètres cliniques, ECG
et angiographiques prédit efﬁcacement les LMO et identiﬁe les patients à haut risque de
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Background
The restoration of coronary ﬂow by transluminal coro-
nary angioplasty has dramatically improved the prognosis of
STEMI [1]. However, the positive impact of advances in the
quality of PCI has been limited by the persistence of coro-
nary microcirculatory obstructive injuries that jeopardize
optimal myocardial reperfusion.
MO injuries that develop during an acute myocardial
infarction have been described as the ‘‘no-reﬂow’’ phe-
nomenon, which remains a frequent, yet underestimated,
complication during STEMI [2—4]. MO lesions are associ-
ated with poor outcome in patients undergoing PCI, with
o
a
e
os droits réservés.
ncreased rates of adverse cardiovascular events and an
nhanced LV remodelling process [4—7]. The development
f microcirculatory injuries after PCI depends on multiple
actors, including ischaemic and reperfusion injuries, but
ts precise pathophysiology remains partially unknown [8,9].
arly detection of MO after PCI is still challenging, but it
ight help clinicians to identify patients at higher risk for
omplications [2].
Angiographic variables such as TIMI ﬂow frame count
r myocardial blush assessment provide partial information
bout quality of microcirculatory perfusion [10]. ST-segment
levation resolution has been strongly correlated with
utcome after MI but has not been speciﬁcally evalu-
5a
g
t
a
p
r
p
a
e
c
p
i
t
o
M
P
S
≥
i
P
w
t
t
w
t
c
p
a
w
m
m
s
d
a
c
g
S
A
d
o
t
a
u
t
a
a
i
u
w
n
p
d
u
7
a
a
a
p
(
c
w
l
w
t
a
l
i
o
E
S
9
s
e
i
a
l
l
m
w
C
B
u
t
A
b
E
w
g
s
s
p
t
o
o
g
i
e
c
r
6
m
t
t14
ted for microcirculatory injury detection [11]. Previous
roups reported the successful use of myocardial con-
rast echocardiography [5,12] or intracoronary ﬂow Doppler
ssessment/index of microcirculatory resistance [13] to
redict MO lesions. However, these latter methods might
equire speciﬁc devices and/or highly trained teams. Thus,
hysicians still need simple, accurate tools to promptly
ssess the success of reperfusion therapy in STEMI [2].
The aim of this study was to analyse the clinical,
lectrical and angiographic factors associated with micro-
irculatory injuries, and to establish a bedside score for
rediction of MO at the acute stage of STEMI, using CMR
maging as the standard of reference. Moreover, we aimed
o assess the prognostic value of this MO score for prediction
f clinical outcome during the ﬁrst year after STEMI.
aterials and methods
atient selection
TEMI was deﬁned as chest pain that persisted for
30minutes associated with ST-segment elevation ≥ 0.1mV
n at least two contiguous electrocardiographic leads [4].
atients referred to our institution with STEMI, who under-
ent revascularization by primary or rescue PCI after
hrombolysis failure, within the ﬁrst 12 hours of evolu-
ion, were screened for inclusion. We excluded patients
ith cardiogenic shock, left bundle branch block on ini-
ial ECG, or severe chronic renal failure, and patients with
ontraindication to magnetic resonance imaging (claustro-
hobia, ferromagnetic foreign body, pacemaker, etc.).
Standard clinical and biological characteristics were
ssessed at baseline and creatine phosphokinase peak value
as determined from consecutive blood sample measure-
ents. Time to efﬁcient revascularization (expressed in
inutes) was calculated as the delay between onset of
ymptoms and completion of PCI. Overweight status was
eﬁned as a body mass index > 27 kg/m2. Creatinine clear-
nce was calculated using the Cockroft-Gault method.
Our local ethics committee approved the study, which
omplied with the Declaration of Helsinki, and all patients
ave their written consent before inclusion.
TEMI management
ll patients included in the study were treated in accor-
ance with international guidelines and the local protocols
f our mobile care units [4]. Thrombolytic therapy was given
o patients when PCI could not be achieved within 2 hours
fter ﬁrst medical contact, using tenecteplase (0.5mg/kg)
nless contraindicated. Rescue PCI was proposed in case of
hrombolysis failure, deﬁned as persistence of chest pain
nd ST-segment elevation regression of < 50%, 90minutes
fter tenecteplase bolus [4].
Before catheterization, patients received aspirin 250mg
ntravenously, a clopidogrel 300mg bolus dose and an
pstream abciximab loading dose (0.25mg/kg of body
eight), at the discretion of the physician. After coro-
ary angiography, all patients (except those previously
retreated) received ad hoc abciximab as a 0.25mg/kg bolus
ose followed by a 12-hour infusion at 0.125g/kg/min,
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nless contraindicated. Heparin (initial bolus dose of
0U/kg) or enoxaparin (initial bolus dose of 1mg/kg) were
dministered during the procedure to achieve adequate
nticoagulation goals. Immediately after the procedure,
clopidogrel loading dose of up to 600mg was com-
leted. Patients were treated routinely with aspirin
325mg/day) and clopidogrel (75mg/day). Angiotensin-
onverting enzyme inhibitors, beta-blockers and statins
ere administered according to current international guide-
ines [4]. The culprit lesion was treated by stenting, that
as performed directly, after balloon predilation or use of
hrombectomy device, at the discretion of the operator. Pre-
nd post-PCI antegrade angiographic ﬂows above the culprit
esion were reviewed retrospectively and classiﬁed accord-
ng to the TIMI criteria by two operators who were unaware
f the CMR results [14].
lectrocardiographic analysis
tandard 12-lead ECGs were registered before, then
0minutes and 24 hours after revascularization, using a
peed of 25mm/s and amplitude of 10mm/mV. ST-segment
levation was measured manually at 60ms after the J point
n three successive QRS-T complexes in all the derivations,
nd the sum of the ST-segment elevation (STsum) was calcu-
ated. The value of the ST-segment elevation in the single
ead with the most prominent deviation (STmax) was also
easured. The percentage of resolution of both variables
as assessed 90minutes and 24 hours after PCI.
MR analysis
etween day 4 and day 8 after PCI, all included patients
nderwent CMR by two investigators who were unaware of
he clinical, electrocardiographic and angiographic ﬁndings.
ll CMR studies were carried out using a 1.5 T whole-
ody magnetic resonance scanner (Symphony TIM, Siemens,
rlangen, Germany), with a 12-element surface coil. Images
ere acquired in end-inspiration breath-hold and under ECG
ating.
Two CMR sequences were used, as follows. Cine
equences (steady-state free precession) were acquired in
hort axis for global function analysis with the following
arameters: repetition time/echo time, 40/1.8ms; slice
hickness, 6mm; no gap between slice; ﬂip angle, 65◦; ﬁeld
f view, 350× 350mm; matrix, 148× 256; temporal res-
lution, 40ms. Delayed enhancement (inversion-recovery
radient-echo) sequences were acquired 10minutes after
ntravenous administration of Gd-DOTA 0.2 mmol/kg,
ncompassing the LV in short-axis, four-chamber and two-
hamber orientations. The sequences parameters were:
epetition time/echo time, 780/1.56ms; slice thickness,
mm; spacing, 0; ﬂip angle, 10◦; ﬁeld of view, 350× 400 cm;
atrix, 152× 134. The inversion time was 270—325ms (set
o null normal myocardial). End-diastolic phase was chosen
o set the acquisition window.
All examinations were transferred to a computer
orkstation (Leonardo, Siemens, Erlanguen, Germany).
uantitative and qualitative analyses were performed by
wo independent observers blinded to other data. LV vol-
mes (indexed to body surface area), LVEF and mass were
easured according to Simpson’s rule.
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The presence and extent of myocardial infarction and
MO were analysed qualitatively and quantitatively, using
a 17-segment LV model. Myocardial infarction was deﬁned
on delayed contrast images as a hyperintense area in the
LV myocardial wall supplied by the infarct-related artery.
Myocardial necrosis extent was deﬁned qualitatively as
subendocardial (extent < 50% of whole wall thickness in more
than half of the segments showing myocardial enhancement)
or transmural (extent > 50% in more than half of the seg-
ments showing myocardial enhancement). MO was deﬁned
on delayed contrast enhanced images as a hypointense zone
within the hyperenhanced infarcted zone [15]. The quan-
titative size of myocardial infarct and MO were computed
by Simpson’s method [15]. The extent of myocardial infarct
and MO were expressed as a percentage of the total LV mass
as follows: myocardial infarct extent (%) = (hyperenhanced
area/LV area)× 100. MO extent (%) was computed as follows:
hypoenhanced extent = (hypoenhanced area/LV area)× 100.
Follow-up
Clinical follow-up was carried out at clinical visits and/or
through phone contact. We collected data prospectively
regarding adverse cardiovascular events during the ﬁrst year
after STEMI. Cardiovascular adverse events were deﬁned as
cardiac death, acute congestive heart failure requiring hos-
pital admission and intravenous infusion of diuretics, stroke,
acute coronary syndrome and urgent PCI.
Statistical analysis
Statistical analysis was performed with SPSS 15.0 software
for Windows (SPSS, Chicago, IL, USA). Data are expressed as
mean and standard error of the mean and the normality of
their distribution was assessed by the Kolmogorov-Smirnov
test. Categorical and continuous variables were compared
using the Chi2 or Fisher’s exact tests and Student’s t test,
respectively. Continuous variables were correlated using
Pearson’s coefﬁcients.
For MO score estimation, we ﬁrst performed univariate
analysis to identify variables potentially associated with the
presence of MO lesions. Next, we estimated the independent
predictors of MO using a multivariable binary logistic regres-
sion analysis, including the different variables identiﬁed by
the univariate analysis (˛ = 0.25). Interactions between vari-
ables were introduced into the model to take the potential
colinearities into account. Logistic regression was used to
perform multivariable analysis and gain an estimation of the
variables for the MO score (˛ = 0.05). Finally, we designed an
MO score based on this logistic model in which clinical rele-
vant variables were balanced by a user-friendly coefﬁcient.
For quality assessment, the MO score was ﬁrst validated
by the CART method, with cross-validation based on the
jack-knife algorithm [16]. The CART methodology provides
a hierarchical evaluation of prognostic variables. Firstly,
it determines, for each variable, the cut-off values that
optimize, in this instance, the identiﬁcation of MO. Sec-
ondly, CART determines the optimal prognostic variable.
This algorithm involves recursive subdivisions of a group
of subjects on the basis of the choice of optimal cut-off
points of the optimal prognostic variables, maximizing clas-
sical split criteria [17]. This method has been successfully
w
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cigure 1. Study ﬂow chart. ECG: electrocardiogram; LBBB: left
undle branch block; MRI: magnetic resonance imaging; STEMI: ST-
egment elevation myocardial infarction.
pplied in various clinical cardiovascular research studies
18—20]. We provided a cross-validation approach using the
lassical jack-knife algorithm [21,22]. This sampling tech-
ique involves discarding one patient at a time and ﬁtting a
ew model for the remaining patients (N-1), examining the
core for its effectiveness in prediction.
Patients’ classiﬁcation after identiﬁcation of MO lesions
as used as a reference for receiver operating characteristic
urve analysis. AUCs were compared using Hanley’s method
nd z statistics.
Patient survival of events was analysed and Kaplan-Meier
urves were constructed. Differences between survival
urves were evaluated using the log-rank test. Cox propor-
ional hazards regression was used to identify independent
orrelates of 1-year occurrence of adverse events (˛ = 0.05).
esults
aseline characteristics of the patients
etween January 2006 and August 2008, 165 patients with
TEMI were admitted to our institution, 112 of who fulﬁlled
he inclusion criteria (Fig. 1). Baseline characteristics of the
atients are displayed in Table 1.
igh incidence of MO lesions identiﬁed by CMR
nalysis
icrocirculatory injuries were identiﬁed in 63 (56%)
atients. The incidence of MO lesions increased when the
alues of post-PCI TIMI ﬂow and STsum regression decreased
Fig. 2). Overall, the incidence of MO lesions was 45% in
atients with a ﬁnal TIMI 3 ﬂow (n = 80), 82% in patients
ith a ﬁnal TIMI < 3 ﬂow (n = 32) and 42% in patients with
0-minute STsum regression > 70% (n = 66).
Age, location of myocardial infarction and pharmacologi-
al management (Table 1) were identical in both groups. The
linical TIMI score and incidence of thrombolysis failure were
516 N. Amabile et al.
Table 1 Baseline characteristics of patients with and without MO lesions.
All patients MO group No MO group p
(n = 112) (n = 63) (n = 49)
Men 93 (83) 54 (86) 39 (79) 0.39
Age (years) 57.8± 1.1 59.7± 1.4 56.1± 1.8 0.18
TIMI risk score (STEMI) 2.6± 0.2 3.1± 0.3 2.1± 0.3 0.01
Cardiovascular risk factors
Hypertension 42 (38) 22 (36) 20 (41) 0.56
Diabetes 19 (17) 12 (19) 7 (14) 0.48
Active smoking 66 (59) 31 (50) 35 (71) 0.02
Body mass index (kg/m2) 26.6± 0.4 26.9± 0.4 26.1± 0.7 0.34
Dyslipidaemia 44 (42) 19 (30) 20 (40) 0.27
Previous history of CAD 17 (15) 6 (10) 11 (22) 0.06
Time to efﬁcient revascularization (min) 205± 11 244± 17 154± 10 < 0.001
Thrombolysis failure 10 (9) 9 (15) 1 (2) 0.02
Culprit lesion
Left anterior descending artery 56 (50) 34 (54) 22 (45) 0.35
Circumﬂex artery 11 (10) 5 (8) 6 (12) 0.44
Right coronary artery 45 (40) 24 (38) 21 (43) 0.61
Peak CPK (IU/L) 2735± 243 3755± 351 1467± 220 < 0.001
Initial ﬁbrinogen (g/L) 3.78± 0.16 3.89± 0.25 3.72± 0.19 0.59
Initial WBC count (/mm3) 11.390± 322 11.380± 430 11.400± 514 0.97
Pharmacological management
Upstream abciximab treatment 31 (28) 19 (31) 12 (25) 0.44
Post-PCI abciximab infusion 96 (88) 54 (88) 42 (88) 0.87
Coronary angiography ﬁndings
Initial TIMI ﬂow 0.88± 0.1 0.76± 0.13 1.04± 0.17 0.19
Post-PCI TIMI ﬂow 2.69± 0.05 2.52± 0.07 2.9± 0.05 < 0.001
Direct stenting 57 (51) 32 (51) 25 (52) 0.89
Use of thrombectomy device 29 (26) 22 (35) 7 (14) 0.02
One-vessel disease 46 (41) 29 (46) 17 (35) 0.26
Two-vessel disease 40 (36) 22 (35) 18 (37) 0.82
Three-vessel disease 26 (23) 12 (19) 14 (29) 0.21
Presence of collateral vessels 36 (32) 15 (24) 21 (42) 0.10
Electrocardiographic ﬁndings
90-minute STsum regression (%) 70.9± 2.6 61.5± 3.5 84.8± 2.8 < 0.001
24-hour STsum regression (%) 71.6± 2.8 66.5± 3.9 80.5± 3.7 0.01
90-minute STmax regression (%) 66.7± 2.6 57.6± 3.4 80.1± 3.5 < 0.001
24-hour STmax regression (%) 70.3± 2.5 63.4± 3.3 81.3± 3.1 < 0.001
Data are mean± standard error of the mean or number (%). CAD: coronary artery disease; CPK: creatine phosphokinase; MO: microvas-
cular obstruction; PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction; STmax: the value of
the ST-segment elevation in the single lead with the most prominent deviation; ST : the sum of the ST-segment elevation; TIMI:
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igher in patients with MO injuries. Moreover, 9/10 patients
ith thrombolysis failure had MO lesions. The ischaemic time
as longer and the creatine phosphokinase peak was higher
n patients with MO injuries. Although the baseline angio-
raphic TIMI ﬂows were similar, the ﬁnal mean TIMI ﬂow
as higher in patients without MO. As expected, the ST-
egment regression indices were superior in patients without
O lesions.
Table 2 depicts CMR ﬁndings in the two groups of patients:
ransmural infarction extension was more frequent, infarct
ize was larger, LVEF was lower and LV end-systolic volume
T
ﬁ
s
isum
as higher in patients with MO. Finally, the incidence of
ericardial effusion was higher in patients with STEMI com-
licated with microcirculatory injuries.
rediction of MO lesions with a
ultiparametric scoreable 3 shows that time to efﬁcient revascularization, TIMI
nal grade, thrombolysis failure and 90-minute STsum regres-
ion were associated with the presence of microvascular
njuries on CMR in the logistic regression multivariable anal-
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Table 2 Cardiac magnetic resonance imaging analysis.
All patients MO group No MO group p
(n = 112) (n = 63) (n = 49)
PCI—CMR delay (days) 5.5± 0.3 5.3± 0.4 5.6± 0.5 0.62
Transmural necrosis 86 (77) 62 (97.5) 24 (50.0) < 0.001
Non-transmyocardial necrosis 26 (23) 1 (2.3) 25 (50.0) < 0.001
LVEF (%) 49.7± 1.1 46.7± 1.5 53.4± 1.6 0.003
LV end-systolic volume (ml/m2) 35.1± 1.3 37.7± 1.8 31.0± 1.8 0.01
LV end-diastolic volume (ml/m2) 70.4± 1.8 72.2± 2.2 67.3± 2.8 0.17
LV mass (g/m2) 77.3± 1.7 79.3± 2.5 73.8± 1.9 0.09
Infarct size (% LV) 14.5± 1.1 18.7± 1.2 9.0± 1.3 < 0.001
MO extent (% LV) 1.8± 0.3 2.8± 0.5 0 < 0.001
Pericardial effusion 28 (25) 24 (39) 4 (9) < 0.001
Data are mean± standard error of the mean or number (%). MO: microvascular obstruction; LV: left ventricle/ventricular; LVEF: left
ventricular ejection fraction; PCI: percutaneous coronary intervention
Figure 2. Prevalence of MO lesions as a function of 90-minute
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Using the CART method with cross-validation, we com-STsum regression and ﬁnal TIMI ﬂow (*p < 0.001 with Chi test). MO:
microvascular obstruction; STsumR: regression of the sum of the ST-
segment elevation; TIMI: Thrombolysis In Myocardial Infarction.
ysis. Moreover, we observed signiﬁcant correlations between
MO extent, 90-minute STsum regression and TIMI ﬁnal grade
(Table 3).
A multiparametric score was built using coefﬁcients
designed for easy clinical practice (Table 4). Although
thrombolysis failure was associated initially with MO lesions
in the univariate analysis, it did not reach statistical sig-
niﬁcance in the multivariable model because of the lack of
power of the variable, related to the lack of events (n = 10
thrombolysis failure). However, as this variable is highly clin-
ically relevant, it was included in the score calculation.
When classifying patients in the MO and no MO groups as
a reference for the receiver operating characteristic curve
(Fig. 3A), the AUC was 0.87± 0.03 (p < 0.001). The optimal
usable cut-off value of the score was > 4, with 84% sensitiv-
ity and 82% speciﬁcity for MO prediction (positive predictive
p
o
t
w.
alue, 83%; negative predictive value, 79%). Similar results
ere observed in the speciﬁc subgroup of patients with
nal TIMI 3 ﬂow: the AUC was 0.85± 0.04 (p < 0.001) with
ensitivity of 78% and speciﬁcity of 88% for prediction of
icrovascular injuries.
Receiver operating characteristic analysis was applied to
T-regression variables, time to efﬁcient revascularization
nd ﬁnal TIMI grade variables (Fig. 3B—D). Although 90-
inute STsum regression, 90-minute STmax regression, time to
fﬁcient revascularization and ﬁnal TIMI grade correctly dis-
riminated between patients with and without MO lesions,
he MO score test was more accurate, with a larger AUC
p < 0.05 compared with previous variables; z statistics).
oreover, sensitivity and speciﬁcity were higher with the
O score than with ST-regression indices (Table 5).
The MO score correlated signiﬁcantly with infarct
ize (r = 0.36, p = 0.001) and MO extent (r = 0.48,
< 0.001), and correlated inversely with LVEF (r =—0.35,
< 0.001). Patients with MO score > 4 had a larger
yocardial infarction zone (17.5± 1.2 vs 11.9± 1.4%
V, p = 0.003), lower LVEF (46.6± 1.4 vs 53.2± 1.6%,
= 0.003), larger end-diastolic LV volume (73.9± 2.4
s 66.9± 2.4mL/m2, p = 0.045) and larger end-
ystolic LV volume (38.6± 2.0 vs 31.4± 1.5mL/m2,
= 0.005).
redictors of MO lesions in univariable and
ultivariable models
nivariate analysis revealed that MO score > 4, ﬁnal
IMI ﬂow< 3, 90-minute STsum regression < 50% and time
o efﬁcient revascularization > 200minutes were associ-
ted with an increased frequency of microcirculatory
njuries, whereas previous dyslipidaemia, three-vessel coro-
ary artery disease and previous history of coronary artery
isease were associated with a lower incidence of MO
esions.ared two strategies: use of the MO score vs a combination
f the other predictors of MO lesions. We observed that
he MO score alone correctly identiﬁed 84% of the patients
ith MO (cross-validation), whereas the combination of
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Table 3 Multivariable predictors for the presence of MO lesions on cardiac magnetic resonance imaging.
Multivariable logistic regression analysis OR [95% CI] p
90-minute STsum regression (per %) 0.96 [0.95—0.99] 0.02
Post-PCI TIMI ﬂow (per unit) 0.28 [0.08—0.92] 0.03
Time to efﬁcient revascularization (per min) 1.007 [1.002—1.013] 0.01
Thrombolysis failure — 0.99
Active smoking 0.62 [0.23—1.68] 0.35
Male sex 3.16 [0.8—12.9] 0.11
Proximal LAD culprit lesion 2.66 [0.81—8.8] 0.11
Correlations between MI size, MO extent and
continuous variables included in MO score calculation
Infarct size, % LV MO extent, % LV
r p r p
90-minute STsum regression − 0.21 0.06 − 0.39 < 0.001
Post-PCI TIMI ﬂow − 0.27 0.02 − 0.46 < 0.001
Time to efﬁcient revascularization 0.24 0.03 0.07 0.55
CI: conﬁdence interval; MI: myocardial infarction; MO: microvascular obstruction; LAD: left anterior descending coronary artery; OR:
odds ratio; PCI: percutaneous coronary intervention; STsum: the sum
Infarction.
Table 4 Calculation of the microvascular obstruction
score.
MO score
Sex
Female 0
Male 2
Thrombolysis failure
No 0
Yes 2
Time to efﬁcient revascularization
< 100 min 0
100—200 min 1
201—300 min 2
> 300 min 3
Post-PCI TIMI angiographic score
3 0
2 2
< 2 3
Post-PCI 90-minute STsum regression
> 80% 0
71—80% 1
50—70% 2
< 50% 3
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rPCI: percutaneous coronary intervention; STsum: the sum of
the ST-segment elevation; TIMI: Thrombolysis In Myocardial
Infarction.
he other predictors correctly identiﬁed only 76% of the
atients.dverse clinical impact of high MO score value
ollow-up was achieved in 110 patients (two patients lost
uring follow-up) with a mean follow-up of 234± 12 days.
t
w
a
dof the ST-segment elevation; TIMI: Thrombolysis in Myocardial
atients with an MO score > 4 and patients with MO lesions on
nitial MRI (p = 0.004, not shown) had a signiﬁcantly higher
ncidence of adverse cardiovascular events during the ﬁrst
ear after STEMI (Fig. 4). Other predictors of adverse events
re displayed in Table 6. Multiple stepwise Cox regression
nalysis identiﬁed an MO score > 4 and clinical TIMI score
s independent predictors of adverse cardiovascular events
Table 6).
iscussion
he main ﬁndings of this study are that the incidence
f MO lesions is high (56%) in a population of patients
ndergoing PCI for STEMI; that an MO score based on
linical, ECG and angiographic data predicted MO with
n acceptable level of sensitivity and speciﬁcity; and
hat an MO score > 4 was an independent predictor of
dverse cardiovascular events during the ﬁrst year following
TEMI.
Development of MO injuries after PCI depends on various
actors, including thrombus distal embolization, vasospasm,
nhanced oxidative stress, neutrophile capillary plugging,
yocardial oedema and inﬂammation [9]. However, the clin-
cal and pharmacological factors associated with MO lesions
emain partially unknown [9] and its real incidence varies
ccording to its deﬁnition and the method chosen for assess-
ent. Microcirculatory injuries were found in 25—30% of the
atients in the studies using post-PCI TIMI ﬂow measurement
23] and myocardial contrast echocardiography [24,25], but
his percentage increased to 80% in series using post-PCI
yocardial blush determination [26]. Fearon et al. reported
ecently a 52% incidence of MO lesions using microcircula-
ory resistance measurement [13]. Our results are consistent
ith the previous reports from groups using CMR [7,27,28]
nd microcirculatory resistance measurement [13].
The methods currently available to detect MO (myocar-
ial contrast echocardiography, intracoronary Doppler
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Figure 3. Receiver operating characteristic curves for the different MO predictors. MO score (panel A) was the most discriminative
predictor, as shown by its AUC being signiﬁcantly larger than that of 90-minute STsum regression (panel B, continuous line), 90-minute STmax
n (p
ascul
e ST
b
a
b
yregression (panel B, dashed line), time to efﬁcient revascularizatio
under the curve; Eff Revasc: efﬁcient revascularization; MO: microv
single lead with the most prominent deviation; STsum: the sum of th
measurement, CMR) have some methodological limitations
or might not be readily available in all cardiac catheter-
ization facilities. Simple, inexpensive, bedside tools still
might be useful to the cardiologist with no access to the
above-mentioned techniques, who needs to assess quality of
reperfusion after STEMI. We report here that a simple score
based on clinical, ECG and angiographic ﬁndings is accurate
in predicting MO lesion development. The MO score com-
t
s
r
o
Table 5 Sensitivity and speciﬁcity of different indices for the
AUC Optimal
MO score 0.87± 0.03 > 4
90-minute STsum regression 0.76± 0.05 < 80%
90-minute STmax regression 0.73± 0.05 < 70%
AUC: area under the curve; MO: microvascular obstruction; STmax: th
most prominent deviation; STsum: the sum of the ST-segment elevationanel C) or ﬁnal angiographic TIMI ﬂow grade (panel D). AUC: area
ar obstruction; STmax: the value of the ST-segment elevation in the
-segment elevation; TIMI: Thrombolysis In Myocardial Infarction.
ines different types of information but is more sensitive
nd speciﬁc than each of these variables alone, as suggested
y the CART analysis. Furthermore, our multivariable anal-
sis shows that an MO score > 4 is a stronger predictor of MO
han post-PCI TIMI grade or poor ST regression. As the MO
core can be readily available in all catheterization laborato-
ies and can be calculated in the ﬁrst 90minutes after PCI,
ur method ﬁts with the goals of the international guide-
prediction of microvascular obstruction lesions.
cut-off value Sensitivity (%) Speciﬁcity (%)
84 82
71 75
67 70
e value of the ST-segment elevation in the single lead with the
.
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Table 6 Predictors of adverse cardiovascular events during the ﬁrst year after percutaneous coronary intervention for
ST-segment elevation myocardial infarction (univariable and multivariable Cox regression analysis).
Univariable analysis Multivariable analysis
RR [95% CI] p RR adjusted [95% CI] p
MO score > 4 3.57 [1.65—7.69] 0.001 2.60 [1.10—6.60] 0.03
Upstream abciximab treatment 0.16 [0.04—0.66] 0.01 0.19 [0.05—0.81] 0.02
Clinical TIMI risk score (per unit increase) 1.45 [1.23—1.70] < 0.001 1.28 [1.0—1.54] 0.007
CPK peak (per 100 UI increase) 1.02 [1.01—1.03] < 0.001 1.01 [0.99—1.02] 0.06
LVEF (per % increase) 0.65 [0.48—0.88] 0.05 > 0.1
Age (per 1-year increase) 1.03 [1.0—1.06] 0.04 > 0.1
CI: conﬁdence interval; CPK: creatine phosphokinase; LVEF: left ventricular ejection fraction; MO: microvascular obstruction; RR:
relative risk; TIMI: Thrombolysis in Myocardial Infarction.
lines that highlighted the need for a simple tool to predict
microcirculatory injuries [2].
Many groups have previously reported the negative
impact of microcirculatory injuries, identiﬁed on the basis
of a binary approach (occurrence or no occurrence), on LV
function in the short term, with an increased incidence
of adverse cardiovascular events, and in the long term,
with accelerated LV remodelling phenomenon and evolution
towards congestive heart failure [5,7,27,29,30]. Our data
are in line with these previous observations. The MO score
provides clinical prognostic information after STEMI. This
higher occurrence of clinical complications might be con-
ferred by the larger extent of MI, MO lesions and lower LVEF
observed in patients with an MO score > 4. Thus, the MO score
appears to be a useful tool to promptly stratify and identify
patients with a higher risk for clinical complications. These
patients might beneﬁt from more aggressive therapy, such
as intra-aortic balloon counterpulsation [31], or they might
Figure 4. Kaplan—Meier estimates of survival free from adverse
cardiovascular events during the ﬁrst year after STEMI among
patients with an MO score > 4 or ≤ 4. MO: microvascular obstruction;
STEMI: ST-segment elevation myocardial infarction.
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Re suitable candidates for stem cell or growth factor therapy
n the future [13]. Nevertheless, further studies are needed
o evaluate these approaches.
Although our study has several strengths, we also rec-
gnize a number of limitations. Firstly, it is a single-centre
tudy with a limited sample size. In addition, we excluded
atients with cardiogenic shock and chronic renal failure
rom the analysis, thus focusing on those with low-to-
ntermediate risk. The accuracy of the MO score in high-risk
atients has yet to be conﬁrmed. Moreover, the MO score was
alidated by internal cross-validation, according to CART
ethodology, and should be validated prospectively in an
ndependent population of patients with STEMI. Finally, as
ur score includes analysis of the post-PCI TIMI ﬂow grade, it
annot be applied to patients with successful thrombolysis
ho do not undergo emergency PCI.
In summary, the present study reports a high incidence
f MO lesions after PCI for STEMI during the ﬁrst 12 hours
f evolution. MO lesions could be predicted with accept-
ble sensitivity and speciﬁcity using a multiparametric MO
core based on clinical, ECG and angiographic data. An MO
core > 4 is a strong independent predictor of microcircu-
atory lesions and adverse cardiovascular events at 1 year
fter STEMI. Further studies are needed to determine the
rognostic value of this test by using it prospectively in a
arger cohort of patients and studying its potential capac-
ty to identify subgroups of patients that might beneﬁt from
ore intensive therapy after MI.
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